You just read:

Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

News provided by

Sanofi

Jun 11, 2017, 11:01 ET